HBVtech

HBVtech is a preclinical stage gene therapy platform company focused on developing novel and proprietary therapies for chronic infectious diseases. HBVtech’s first treatment, HBVZ10, is designed to cure chronic HBV infections by eliminating the root cause of chronic HBV infections, specifically HBV covalently closed circular DNA (cccDNA), through its optimized AAV8 vector delivering human anti-HB genes. HBVtech is dedicated to addressing the significant unmet medical needs of chronically infected patients worldwide by providing a functional cure.

Therapeutic Developer